HIV vaccines - where are we going?

被引：50

作者：

Heilman, CA ^{[1
]}

Baltimore, D

机构：

[1] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA

[2] CALTECH, Pasadena, CA 91125 USA

来源：

NATURE MEDICINE | 1998年 / 4卷 / 05期

关键词：

D O I：

10.1038/nm0598supp-532

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

[No abstract available]

引用

页码：532 / 534

页数：3

共 38 条

[1] RAPID DEVELOPMENT OF ISOLATE-SPECIFIC NEUTRALIZING ANTIBODIES AFTER PRIMARY HIV-1 INFECTION AND CONSEQUENT EMERGENCE OF VIRUS VARIANTS WHICH RESIST NEUTRALIZATION BY AUTOLOGOUS SERA [J].

ALBERT, J ;

ABRAHAMSSON, B ;

NAGY, K ;

AURELIUS, E ;

GAINES, H ;

NYSTROM, G ;

FENYO, EM .

AIDS, 1990, 4 (02) :107-112

[2] Phenotypic analysis of antigen-specific T lymphocytes [J].

Altman, JD ;

Moss, PAH ;

Goulder, PJR ;

Barouch, DH ;

McHeyzerWilliams, MG ;

Bell, JI ;

McMichael, AJ ;

Davis, MM .

SCIENCE, 1996, 274 (5284) :94-96

[3] PATHOGENICITY OF LIVE, ATTENUATED SIV AFTER MUCOSAL INFECTION OF NEONATAL MACAQUES [J].

BABA, TW ;

JEONG, YS ;

PENNINCK, D ;

BRONSON, R ;

GREENE, MF ;

RUPRECHT, RM .

SCIENCE, 1995, 267 (5205) :1820-1825

[4] Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians [J].

Betts, MR ;

Krowka, J ;

Santamaria, C ;

Balsamo, K ;

Gao, F ;

Mulundu, G ;

Luo, CW ;

NGandu, N ;

Sheppard, H ;

Hahn, BH ;

Allen, S ;

Frelinger, JA .

JOURNAL OF VIROLOGY, 1997, 71 (11) :8908-8911

[5] A vaccine for HIV type 1: The antibody perspective [J].

Burton, DR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (19) :10018-10023

[6] Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development [J].

Cao, HY ;

Kanki, P ;

Sankale, JL ;

DiengSarr, A ;

Mazzara, GP ;

Kalams, SA ;

Korber, B ;

Mboup, S ;

Walker, BD .

JOURNAL OF VIROLOGY, 1997, 71 (11) :8615-8623

[7] VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].

CAO, YZ ;

QIN, LM ;

ZHANG, LQ ;

SAFRIT, J ;

HO, DD .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) :201-208

[8] Analysis of the human env-specific cytotoxic T-lymphocyte (CTL) response in natural human immunodeficiency virus type 1 infection: Low prevalence of broadly cross-reactive env-specific CTL [J].

Carmichael, A ;

Jin, X ;

Sissons, P .

JOURNAL OF VIROLOGY, 1996, 70 (12) :8468-8476

[9] GENOMIC STRUCTURE OF AN ATTENUATED QUASI-SPECIES OF HIV-1 FROM A BLOOD-TRANSFUSION DONOR AND RECIPIENTS [J].

DEACON, NJ ;

TSYKIN, A ;

SOLOMON, A ;

SMITH, K ;

LUDFORDMENTING, M ;

HOOKER, DJ ;

MCPHEE, DA ;

GREENWAY, AL ;

ELLETT, A ;

CHATFIELD, C ;

LAWSON, VA ;

CROWE, S ;

MAERZ, A ;

SONZA, S ;

LEARMONT, J ;

SULLIVAN, JS ;

CUNNINGHAM, A ;

DWYER, D ;

DOWTON, D ;

MILLS, J .

SCIENCE, 1995, 270 (5238) :988-991

[10] Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials [J].

DSouza, MP ;

Livnat, D ;

Bradac, JA ;

Bridges, SH ;

Bryson, Y ;

Hanson, C ;

Matthews, T ;

Moore, J ;

Trkola, A ;

ZollaPazner, S ;

Gorny, M ;

Burton, D ;

Merigan, T ;

McNamara, J ;

Norcross, M ;

Posner, M ;

Robinson, J ;

ViraniKetter, N ;

Barbas, CF ;

Parren, P ;

Katinger, H .

JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (05) :1056-1062

← 1 2 3 4 →